P2 receptors: new potential players in atherosclerosis.
Atherosclerosis is a focal inflammatory disease of the arterial wall. It starts with the formation of fatty streaks on the arterial wall that evolve to form a raised plaque made of smooth muscle cells (SMCs), and infiltrating leukocytes surrounding a necrotic core. The pathogenesis of the atherosclerotic lesion is incompletely understood, but it is clear that a dysfunction of the endothelium, recruitment and activation of inflammatory cells and SMC proliferation have a pivotal role. Over recent years receptors for extracellular nucleotides, the P2 receptors, have been recognized as fundamental modulators of leukocytes, platelets, SMCs and endothelial cells. P2 receptors mediate chemotaxis, cytokine secretion, NO generation, platelet aggregation and cell proliferation in response to accumulation of nucleotides into the extracellular milieu. Clinical trials have shown the benefit of antagonists of the ADP platelet receptor(s) in the prevention of vascular accidents in patients with atherosclerosis. Therefore, we anticipate that a deeper understanding of the involvement of P2 receptors in atheroma formation will open new avenues for drug design and therapeutic intervention.
Di Virgilio
Francesco
F
Department of Experimental and Diagnostic Medicine, Section of General Pathology, Via Borsari 46, I-44100 Ferrara, Italy. fdv@unife.it
Solini
Anna
A
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D018048:Receptors, Purinergic P2 / Q000097:blood / Q000378:metabolism*
D016207:Cytokines; D018048:Receptors, Purinergic P2; D009569:Nitric Oxide; D000255:Adenosine Triphosphate